Tarceva and Metastases to bone - a phase IV clinical study of FDA data

Summary:

Metastases to bone is reported as a side effect among people who take Tarceva (erlotinib hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Zometa, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Metastases to bone when taking Tarceva. It is created by eHealthMe based on reports of 30,795 people who have side effects when taking Tarceva from the FDA, and is updated regularly.

What is Tarceva?

Tarceva has active ingredients of erlotinib hydrochloride. It is often used in lung cancer. eHealthMe is studying from 31,036 Tarceva users. Check the latest studies of Tarceva.

What is Metastases to bone?

Metastases to bone (cancer spreads to bone) is found to be associated with 1,127 drugs and 902 conditions by eHealthMe. Check the latest studies of Metastases to bone.

On Jul, 19, 2026

30,795 people reported to have side effects when taking Tarceva.
Among them, 150 people (0.49%) have Metastases to bone.

Among these 150 people:

* Approximation only. Some reports may have incomplete information.

Do you take Tarceva and have Metastases to bone?

- Check whether Metastases to bone is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tarceva:

Tarceva (31,036 reports)

Metastases to bone treatments and more:

Metastases to bone (51,059 reports)

How severe was Metastases to bone and when was it recovered:

Metastases to bone in Tarceva

Expand to all the drugs that have ingredients of erlotinib hydrochloride:

Metastases to bone and drugs with ingredients of erlotinib hydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tarceva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Metastases to bone:

Metastases to bone (1,127 drugs)

Browse all the conditions that are associated with Metastases to bone:

Metastases to bone (902 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on erlotinib hydrochloride (the active ingredients of Tarceva) and Tarceva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.